Marinomed Biotech AG

Marinomed Biotech AG announces unanimous approval of the restructuring plan by creditors

Marinomed Biotech AG publishes clinical data for decongestant Carragelose nasal spray in peer-reviewed International Journal of General Medicine

Marinomed Biotech AG begins contract negotiations for the sale of the Carragelose portfolio

Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal

Release according to Article 135, Section 1 BörseG with the objective of Europe-wide distribution

Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops

Marinomed Biotech AG: Simon Nebel, buy

Marinomed Biotech AG: Andreas Grassauer, buy

Marinomed Biotech AG: Eva Prieschl-Grassauer, buy

Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share

Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights

Marinomed Biotech AG: First Carragelose products receive new Medical Device Regulation (MDR) certification

Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights

Marinomed Biotech AG reports preliminary financial figures for the first half of 2024

Marinomed Biotech AG: Court opens restructuring proceedings without self-administration

Marinomed Biotech AG aims for financial reorganization by restructuring proceedings without self-administration

Marinomed Biotech AG applies for court restructuring proceedings without self-administration

Marinomed Biotech AG secures licensure with leading Consumer Health Care player for the distribution of Carragelose® products in Europe

Marinomed Biotech AG: Invitation to the 7th Annual General Meeting on Thursday, June 20, 2024, at 13:00 (Vienna time)

Marinomed Biotech AG announces results for the first quarter of 2024

Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios

Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets